Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 11,176 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Completed No phase listed Observational

The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease

NCT01055730
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Pulmonary rehabilitation
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Concord, California • Daly City, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Nov 5, 2026, 9:05 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

NCT01806909
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-H5-Vtn
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Nov 5, 2026, 9:05 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Normative QEEG/ERP Data for Healthy Volunteers

NCT05869032
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
20 Years to 59 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Nov 5, 2026, 9:05 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Completed No phase listed Observational

Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

NCT01522833
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Nov 5, 2026, 9:05 PM EST
Active, not recruiting Not applicable Interventional

Preoperative Irradiation for Stage I Breast Cancer

NCT05464667
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
Parul Barry
Other
Eligibility
50 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

NCT03473236
View directory record Official record
Conditions
Safety Issues
Interventions
GB002, Generic Dry Powder Inhaler, Placebo
Drug · Device
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Nov 5, 2026, 9:05 PM EST
Withdrawn Phase 1 Interventional

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer

NCT03029871
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage I
Interventions
Ad5-yCD/mutTKSR39rep-ADP Adenovirus
Biological
Lead sponsor
Benjamin Movsas, M.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Nov 5, 2026, 9:05 PM EST
Terminated Early Phase 1 Interventional

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

NCT03724409
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
[90]Y-DOTATOC
Drug
Lead sponsor
Sandeep Laroia
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Nov 5, 2026, 9:05 PM EST
Active, not recruiting Phase 1 Interventional

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

NCT05797233
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell
Interventions
Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Completed Phase 2 Interventional Results available

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

NCT00040664
View directory record Official record
Conditions
HIV Infection
Interventions
ritonavir, fosamprenavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Nov 5, 2026, 9:05 PM EST
Terminated Phase 1 Interventional Results available

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

NCT04315233
View directory record Official record
Conditions
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Interventions
Ribociclib, Belinostat
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Salt Lake City, Utah • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Recruiting Not applicable Interventional

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

NCT06184152
View directory record Official record
Conditions
HCC, Hepatocellular Carcinoma
Interventions
CEUS imaging, aMRI imaging
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Terminated Phase 1 Interventional Results available

A Study Of PF-06647263 In Patients With Advanced Solid Tumors

NCT02078752
View directory record Official record
Conditions
Neoplasms, Triple-Negative Breast Cancer
Interventions
PF-06647263
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Boston, Massachusetts • Detroit, Michigan • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Nov 5, 2026, 9:05 PM EST
Enrolling by invitation Phase 3 Interventional

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

NCT05844449
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
1 Year and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
18
States / cities
Orange, California • Palo Alto, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Completed No phase listed Observational Results available

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

NCT01729455
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Benlysta, Standard of Care (SoC) Therapy
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
3,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
102
States / cities
Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Active, not recruiting Phase 2 Interventional

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Active, not recruiting Phase 1 Interventional

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

NCT04420754
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Interventions
AIC100 CAR T Cells
Biological
Lead sponsor
AffyImmune Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 5, 2026, 9:05 PM EST
Terminated Not applicable Interventional Results available

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

NCT02881554
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Vascular Thrombosis
Interventions
Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 5, 2026, 9:05 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

NCT03589326
View directory record Official record
Conditions
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Interventions
Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Nov 5, 2026, 9:05 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Predicting Sleep, Smoking, and Lung Health Disparities in African American Adults

NCT03534076
View directory record Official record
Conditions
Sleep, Lung Diseases, Smoking
Interventions
Cohort Observational study
Other
Lead sponsor
Temple University
Other
Eligibility
40 Years to 67 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 5, 2026, 9:05 PM EST
Active, not recruiting Phase 3 Interventional

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178
View directory record Official record
Conditions
Advanced HER2+Breast Cancer
Interventions
Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Fayetteville, Arkansas • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 5, 2026, 9:05 PM EST
Terminated Phase 1 Interventional

Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085
View directory record Official record
Conditions
Impaired Hepatic Function, Healthy
Interventions
ALXN2050
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Nov 5, 2026, 9:05 PM EST
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies

NCT01967043
View directory record Official record
Conditions
Solid Tumor
Interventions
Oraxol
Drug
Lead sponsor
Kinex Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Aurora, Colorado • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Nov 5, 2026, 9:05 PM EST